CA-ENLIGHTED
23.5.2023 14:31:34 CEST | Business Wire | Press release
Today Enlighted, a leading proptech company owned by Siemens, announced a new engagement with World Wrestling Entertainment (WWE) to support its vision of a smart, energy efficient headquarters. The leader in global entertainment that can be seen in more than 1 billion homes worldwide will use Enlighted’s intelligent lighting control, smart sensors, IoT data services and real time location services (RTLS) to achieve occupancy-based energy savings, optimal space management and provide the most productive environment for WWE employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005437/en/
(Photo: Business Wire)
WWE is headquartered in Stamford, Connecticut, with over 400,000 square feet of multi-purpose space including office space, studios, production and post-production facilities, conferencing, event, and outdoor terrace spaces. With the size and complexity of space types, it is essential for WWE to understand and optimize its real estate footprint using technology and software with the flexibility to address a range of uses. As part of a major renovation and digital transformation initiative, with almost 2,000 sensors over a wireless, fault-tolerant network at WWE will enable:
Enlighted Lighting Solution: Occupancy-based intelligent lighting control with flexible configurations for task tuning, daylight harvesting and efficient lighting of WWE spaces will result in bottom line energy savings and progression of WWE’s carbon neutrality.
Enlighted Data Services: Collecting data 65 times per second from sensors that measure movement, temperature and power, WWE will use specialized visualization dashboards to derive key insights for space design decisions.
Location Intelligence: WWE will use the same lighting sensing environment to reliably track assets, ranging from high value assets (memorabilia, collectibles) to operational assets (mail carts, merchandise samples, packages) in real-time for movement analysis and improved inventory management.
With Enlighted’s lighting controls as the foundation, WWE will be solving multiple IoT use cases and utilizing the open APIs, WWE will have central management, a ‘single pane of glass’ into operations.
“The new WWE headquarters is comprised of spaces intended for a variety of very different uses,” said Rajan Mehta, Chief Technology Officer, WWE. “The Enlighted IoT Smart Building technology will make it possible for us to realize enormous energy savings, increase our operating efficiencies and use data to capture building activity for intelligent data-driven space decisions. IoT-based asset tracking and process flow improvements will make our headquarters truly a smart building.”
“Space utilization isn’t just a matter of knowing how many people are in an office or production facility at a given moment—it’s about understanding how employees and guests are moving and interacting with spaces,” said Stefan Schwab, CEO of Enlighted. “The lighting-based sensors at WWE will capture vast amounts of data that WWE can use for a refined view of activity across all of their buildings. With the scalability of cloud storage, the company will be able to identify trends and preferences as they examine building usage data over time.”
About Enlighted
Enlighted is a leading proptech provider of IoT solutions at the intersection of people, space, and work. We offer a unique combination of cognitive environmental IoT sensors and lighting controls that connect to intelligent workplace experience apps, offering a singular, scalable, interoperable solution to address a spectrum of building, space, and productivity needs. Our customers leverage these solutions to enable occupant well-being, greater business efficiencies and momentum toward their sustainability goals. Enlighted is part of Building Robotics, Inc., a Siemens company. For more information, please visit us at enlightedinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005437/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom